USP Standard Tretinoin Skincare Retinoic acid CAS 302-79-4 for acne treatment

Tretinoin More Info

Tretinoin, also known as all-trans retinoic acid (ATRA), is a derivative of vitamin A used primarily for the treatment of acne and acute promyelocytic leukemia (APL). Its effectiveness in dermatology extends to addressing photoaging and other skin conditions.

Mechanism of Action

1. Acne Treatment
Tretinoin acts by binding to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in keratinocytes, leading to:
Normalization of Follicular Keratinization: It reduces the cohesiveness of keratinocytes, preventing clogged pores and microcomedone formation.
Increased Cell Turnover: Tretinoin stimulates mitotic activity in follicular epithelial cells, promoting the expulsion of comedones.
Anti-inflammatory Effects: It down-regulates inflammatory mediators, including toll-like receptor (TLR)-2, which is implicated in acne inflammation.
Enhanced Penetration of Other Medications: Tretinoin can improve the efficacy of other topical treatments when used in conjunction.
2. Acute Promyelocytic Leukemia
In APL, tretinoin induces differentiation in promyelocyte cells by degrading the RARA-PML fusion oncogene, which is crucial for the proliferation of these cancer cells. This action leads to maturation of leukemic cells and has been shown to produce significant clinical responses.

Applications

Tretinoin is indicated for:
Topical Use: Treatment of acne vulgaris and various skin conditions such as photoaging and fine wrinkles.
Oral Use: Management of acute promyelocytic leukemia, particularly in patients with specific genetic mutations (RARA-PML fusion).

Routes of Administration

Tretinoin is available in two primary forms:
Topical: Creams or gels applied directly to the skin (available concentrations include 0.025%, 0.05%, and 0.1%).
Oral: Capsules used for treating APL, typically administered for up to three months.

Safety and Side Effects

Tretinoin can cause a range of side effects, which vary depending on the route of administration:
1. Common Side Effects
Topical Form: Skin irritation, redness, burning sensation, peeling, dryness, and increased sensitivity to sunlight.
Oral Form: Fatigue, headache, nausea, vomiting, dizziness, and potential elevation in cholesterol levels.
2. Serious Side Effects
RA-APL Syndrome: A life-threatening condition associated with oral tretinoin that requires immediate medical attention if symptoms like fever or respiratory distress occur.
Neurological Symptoms: Severe headaches or visual disturbances may arise.
Gastrointestinal Issues: Potential for severe abdominal pain or signs of pancreatitis.
Patients using tretinoin should be monitored closely for these adverse effects.

Pharmacokinetics

The pharmacokinetic properties of tretinoin include:
Absorption: Rapidly absorbed when taken orally; topical formulations are also quickly absorbed but can be affected by light and oxygen exposure.
Distribution: Highly protein-bound (>95%), primarily to albumin.
Metabolism: Metabolized mainly in the liver by cytochrome P450 enzymes (CYP3A4, CYP2C8) into various active metabolites. It undergoes glucuronidation as well.
Elimination: Metabolites are excreted in urine and bile. The half-life varies but is generally around 1–2 hours after oral administration.